Literature DB >> 3210656

Malignant mesothelioma of the pleura. A prospective therapeutic study of 132 patients from 1981-1985.

A Calavrezos1, G Koschel, H Hüsselmann, A Taylessani, H P Heilmann, H Fabel, H J Schmoll, H Dietrich, E Hain.   

Abstract

Between March 1981 and February 1985, 93 out of 132 patients with a histologically confirmed diagnosis of malignant pleural mesothelioma were eligible for therapy and were prospectively assigned to receive either combined therapy or best supportive care, according to their personal preferences. Fifty-seven patients underwent multimodal therapy including surgical resection where possible, polychemotherapy, and radiation therapy in case of partial remission. Thirty-six patients received maximal supportive care only, as did 39 patients who were not eligible for treatment. The median survival was 13 months for treated patients compared to 7 for those receiving best supportive care and 5 for patients not amenable to treatment. Median progress-free survival was 6, 2, and 1 month respectively. Surgical resection did not prolong life expectancy within the treated group. In view of significant differences in the distribution of various cofactors over the two study groups, stepwise Cox model analyses were performed. Prognostic nontreatment variables related to prolonged survival were: good performance status, stage I and II, absence of chest pain, age below 50 years, and epithelial histology. Although in the Cox model analyses the survival improvement of patients being treated could be greatly attributed to other cofactors, multimodal treatment showed some prolongation of life expectancy.

Entities:  

Mesh:

Year:  1988        PMID: 3210656     DOI: 10.1007/bf01728801

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  16 in total

1.  Pleuropneumonectomy in the management of diffuse malignant mesothelioma of the pleura. Experience with 29 patients.

Authors:  E G Butchart; T Ashcroft; W C Barnsley; M P Holden
Journal:  Thorax       Date:  1976-02       Impact factor: 9.139

2.  The clinical aspects of mesothelioma.

Authors:  P C Elmes; J C Simpson
Journal:  Q J Med       Date:  1976-07

Review 3.  Malignant mesothelioma. Current status and future prospects.

Authors:  J Aisner; P H Wiernik
Journal:  Chest       Date:  1978-10       Impact factor: 9.410

4.  Phase II study of mitoxantrone in patients with mesothelioma: a National Cancer Institute of Canada Clinical Trials Group Study.

Authors:  E A Eisenhauer; W K Evans; D Raghavan; M J Desmeules; N R Murray; R Stuart-Harris; K S Wilson
Journal:  Cancer Treat Rep       Date:  1986-08

5.  [Retrospective study of 150 cases of mesothelioma in Hamburg area (author's transl)].

Authors:  E Hain; P Dalquen; H Bohlig; A Dabbert; I Hinz
Journal:  Int Arch Arbeitsmed       Date:  1974-03-12

6.  Unexpected longevity of a patient with malignant pleural mesothelioma: report of a case.

Authors:  A Fischbein; Y Suzuki; I J Selikoff; J G Bekesi
Journal:  Cancer       Date:  1978-10       Impact factor: 6.860

7.  Phase II trial of high-dose cisplatin in patients with malignant mesothelioma.

Authors:  D M Mintzer; D Kelsen; D Frimmer; R Heelan; R Gralla
Journal:  Cancer Treat Rep       Date:  1985-06

8.  Pleural mesothelioma.

Authors:  H J Wanebo; N Martini; M R Melamed; B Hilaris; E J Beattie
Journal:  Cancer       Date:  1976-12       Impact factor: 6.860

9.  Malignant mesothelioma. The Eastern Cooperative Oncology Group (ECOG) experience.

Authors:  H J Lerner; D A Schoenfeld; A Martin; G Falkson; E Borden
Journal:  Cancer       Date:  1983-12-01       Impact factor: 6.860

10.  Radiation therapy in the management of patients with mesothelioma.

Authors:  W Gordon; K H Antman; J S Greenberger; R R Weichselbaum; J T Chaffey
Journal:  Int J Radiat Oncol Biol Phys       Date:  1982-01       Impact factor: 7.038

View more
  6 in total

Review 1.  Lung cancer * 8: Management of malignant mesothelioma.

Authors:  C Parker; E Neville
Journal:  Thorax       Date:  2003-09       Impact factor: 9.139

Review 2.  Management of malignant pleural mesothelioma-The European experience.

Authors:  Isabelle Opitz
Journal:  J Thorac Dis       Date:  2014-05       Impact factor: 2.895

Review 3.  Radiotherapy for malignant pleural mesothelioma.

Authors:  E Chapman; E G Berenstein; M Diéguez; Z Ortiz
Journal:  Cochrane Database Syst Rev       Date:  2006-07-19

4.  Factors that impact susceptibility to fiber-induced health effects.

Authors:  Jennifer E Below; Nancy J Cox; Naomi K Fukagawa; Ari Hirvonen; Joseph R Testa
Journal:  J Toxicol Environ Health B Crit Rev       Date:  2011       Impact factor: 6.393

5.  Analysis of the effect of radiotherapy on malignant pleural mesothelioma when given on adjuvant or palliative basis.

Authors:  Hesham A El Hossieny; Fatma Aboulkasem; M Abdel Rahman
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2010-01

6.  Paclitaxel for malignant pleural mesothelioma: a phase II study of the EORTC Lung Cancer Cooperative Group.

Authors:  J van Meerbeeck; C Debruyne; N van Zandwijk; P E Postmus; M C Pennucci; F van Breukelen; D Galdermans; H Groen; P Pinson; M van Glabbeke; E van Marck; G Giaccone
Journal:  Br J Cancer       Date:  1996-09       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.